{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:13:38Z","timestamp":1788408818336,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40119-026-00467-3","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T17:20:53Z","timestamp":1786382453000},"page":"351-363","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Burden of Systemic Inflammation Among Individuals with Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease in Northern China"],"prefix":"10.1007","volume":"15","author":[{"given":"Hongye","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Fugger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zewei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yawei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hangkuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zirui","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoya","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"467_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2025.1529506","volume":"13","author":"XZ Hou","year":"2025","unstructured":"Hou XZ, Wu Q, Yang YT, et al. The epidemiology and burden of atherosclerotic cardiovascular disease in China from 1990 to 2021: findings from the global burden of disease 2021. Front Public Health. 2025;13:1529506. https:\/\/doi.org\/10.3389\/fpubh.2025.1529506.","journal-title":"Front Public Health"},{"issue":"4","key":"467_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41569-018-0119-4","volume":"16","author":"D Zhao","year":"2019","unstructured":"Zhao D, Liu J, Wang M, Zhang X, Zhou M. Epidemiology of cardiovascular disease in China: current features and implications. Nat Rev Cardiol. 2019;16(4):203\u201312. https:\/\/doi.org\/10.1038\/s41569-018-0119-4.","journal-title":"Nat Rev Cardiol"},{"issue":"9888","key":"467_CR3","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0140-6736(13)60687-X","volume":"382","author":"V Jha","year":"2013","unstructured":"Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013;382(9888):260\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(13)60687-X.","journal-title":"Lancet"},{"issue":"9","key":"467_CR4","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.2215\/CJN.10481013","volume":"9","author":"R Minutolo","year":"2014","unstructured":"Minutolo R, Lapi F, Chiodini P, et al. Risk of ESRD and death in patients with CKD not referred to a nephrologist: a 7-year prospective study. Clin J Am Soc Nephrol. 2014;9(9):1586\u201393. https:\/\/doi.org\/10.2215\/CJN.10481013.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"467_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1001\/jamainternmed.2022.6817","volume":"183","author":"L Wang","year":"2023","unstructured":"Wang L, Xu X, Zhang M, et al. Prevalence of chronic kidney disease in China: results from the sixth China chronic disease and risk factor surveillance. JAMA Intern Med. 2023;183(4):298\u2013310. https:\/\/doi.org\/10.1001\/jamainternmed.2022.6817.","journal-title":"JAMA Intern Med"},{"key":"467_CR6","doi-asserted-by":"crossref","unstructured":"Liu X, Ma C, Guo Y, Zhao B, Teng H. Awareness and perceptions on the role of systemic inflammation in atherosclerotic cardiovascular disease and chronic kidney disease: a national study among cardiologists and nephrologists in China [Poster presentation]. ESC Congress 2025, Madrid, Spain.","DOI":"10.1093\/eurheartj\/ehaf784.1658"},{"issue":"44","key":"467_CR7","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1093\/eurheartj\/ehae557","volume":"45","author":"F Mazhar","year":"2024","unstructured":"Mazhar F, Faucon AL, Fu EL, et al. Systemic inflammation and health outcomes in patients receiving treatment for atherosclerotic cardiovascular disease. Eur Heart J. 2024;45(44):4719\u201330. https:\/\/doi.org\/10.1093\/eurheartj\/ehae557.","journal-title":"Eur Heart J"},{"key":"467_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1329256","volume":"15","author":"X Li","year":"2024","unstructured":"Li X, Cui L, Xu H. Association between systemic inflammation response index and chronic kidney disease: a population-based study. Front Endocrinol. 2024;15:1329256. https:\/\/doi.org\/10.3389\/fendo.2024.1329256.","journal-title":"Front Endocrinol"},{"issue":"3","key":"467_CR9","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1161\/01.cir.0000052939.59093.45","volume":"107","author":"TA Pearson","year":"2003","unstructured":"Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499\u2013511. https:\/\/doi.org\/10.1161\/01.cir.0000052939.59093.45.","journal-title":"Circulation"},{"key":"467_CR10","doi-asserted-by":"publisher","unstructured":"Chinese Society of Cardiology, Chinese Medical Association, Cardiovascular Disease Prevention and Rehabilitation Committee of Chinese Association of Rehabilitation Medicine, Cardiovascular Disease Committee of Chinese Association of Gerontology and Geriatrics, & Thrombosis Prevention and Treatment Committee of Chinese Medical Doctor Association. Zhonghua xin xue guan bing za zhi.\u00a02023;51:1\u201321. https:\/\/doi.org\/10.3760\/cma.j.cn112148-20230106-00014","DOI":"10.3760\/cma.j.cn112148-20230106-00014"},{"issue":"4","key":"467_CR11","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1161\/CIRCULATIONAHA.106.628909","volume":"114","author":"DA Morrow","year":"2006","unstructured":"Morrow DA, de Lemos JA, Sabatine MS, et al. Clinical relevance of C-reactive protein during follow-up of patients with acute coronary syndromes in the Aggrastat-to-Zocor Trial. Circulation. 2006;114(4):281\u20138. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.628909.","journal-title":"Circulation"},{"issue":"2","key":"467_CR12","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1136\/jech-2018-211433","volume":"73","author":"Y Dong","year":"2019","unstructured":"Dong Y, Wang X, Zhang L, et al. High-sensitivity C reactive protein and risk of cardiovascular disease in China-CVD study. J Epidemiol Community Health. 2019;73(2):188\u201392. https:\/\/doi.org\/10.1136\/jech-2018-211433.","journal-title":"J Epidemiol Community Health"},{"issue":"2","key":"467_CR13","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1159\/000528693","volume":"9","author":"J Li","year":"2022","unstructured":"Li J, Chen J, Lan HY, Tang Y. Role of C-reactive protein in kidney diseases. Kidney Dis (Basel). 2022;9(2):73\u201381. https:\/\/doi.org\/10.1159\/000528693.","journal-title":"Kidney Dis (Basel)"},{"issue":"13","key":"467_CR14","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1161\/CIRCULATIONAHA.115.018381","volume":"132","author":"EA Bohula","year":"2015","unstructured":"Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015;132(13):1224\u201333. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.115.018381.","journal-title":"Circulation"},{"issue":"10289","key":"467_CR15","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1016\/S0140-6736(21)00520-1","volume":"397","author":"PM Ridker","year":"2021","unstructured":"Ridker PM, Devalaraja M, Baeres FMM, et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase\u00a02 trial. Lancet. 2021;397(10289):2060\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(21)00520-1.","journal-title":"Lancet"},{"issue":"4","key":"467_CR16","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.jjcc.2023.05.006","volume":"82","author":"Y Wada","year":"2023","unstructured":"Wada Y, Jensen C, Meyer ASP, Zonoozi AAM, Honda H. Efficacy and safety of interleukin-6 inhibition with ziltivekimab in patients at high risk of atherosclerotic events in Japan (RESCUE-2): a randomized, double-blind, placebo-controlled, phase\u00a02 trial. J Cardiol. 2023;82(4):279\u201385. https:\/\/doi.org\/10.1016\/j.jjcc.2023.05.006.","journal-title":"J Cardiol"},{"key":"467_CR17","doi-asserted-by":"publisher","unstructured":"Ridker PM, MacFadyen JG, Everett BM, et al. Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial.\u00a0Lancet.\u00a02018;391(10118):319\u2013328. https:\/\/doi.org\/10.1016\/S0140-6736(17)32814-3.","DOI":"10.1016\/S0140-6736(17)32814-3"},{"issue":"11","key":"467_CR18","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1136\/heartjnl-2024-325079","volume":"111","author":"P Sun","year":"2025","unstructured":"Sun P, Liu WN, Qian X, et al. Age-specific prognosis of acute and steady minor elevations in cardiac troponin among non-acute myocardial infarction inpatients: a large real-world cohort study. Heart. 2025;111(11):513\u201321. https:\/\/doi.org\/10.1136\/heartjnl-2024-325079.","journal-title":"Heart"},{"issue":"6","key":"467_CR19","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s00392-025-02645-0","volume":"114","author":"X Chen","year":"2025","unstructured":"Chen X, Liu H, Li L, et al. Atorvastatin versus rosuvastatin in acute myocardial infarction with elevated liver enzymes: a target trial emulation study. Clin Res Cardiol. 2025;114(6):796\u2013808. https:\/\/doi.org\/10.1007\/s00392-025-02645-0.","journal-title":"Clin Res Cardiol"},{"issue":"7","key":"467_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.amjmed.2025.02.029","volume":"138","author":"L Li","year":"2025","unstructured":"Li L, A G, Guo Y, et al. Early \u03b2-blocker use and clinical outcomes in acute myocardial injury: a retrospective cohort study. Am J Med. 2025;138(7):1090-1098.e6. https:\/\/doi.org\/10.1016\/j.amjmed.2025.02.029.","journal-title":"Am J Med"},{"issue":"1","key":"467_CR21","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12889-024-21131-2","volume":"25","author":"Y Cao","year":"2025","unstructured":"Cao Y, Wang W, Xie S, Xu Y, Lin Z. Joint association of the inflammatory marker and cardiovascular-kidney-metabolic syndrome stages with all-cause and cardiovascular disease mortality: a national prospective study. BMC Public Health. 2025;25(1):10. https:\/\/doi.org\/10.1186\/s12889-024-21131-2.","journal-title":"BMC Public Health"},{"issue":"17","key":"467_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26178256","volume":"26","author":"C Carollo","year":"2025","unstructured":"Carollo C, Sorce A, Cirafici E, Ciuppa ME, Mul\u00e8 G, Caimi G. Silent inflammation, loud consequences: decoding NLR across renal, cardiovascular and metabolic disorders. Int J Mol Sci. 2025;26(17):8256. https:\/\/doi.org\/10.3390\/ijms26178256.","journal-title":"Int J Mol Sci"},{"key":"467_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2025.100950","volume":"21","author":"L Lv","year":"2025","unstructured":"Lv L, Rajpura J, Liu M, et al. Prevalence and clinical characteristics of patients with hsCRP testing and test-confirmed systemic inflammation among individuals with atherosclerotic cardiovascular disease with or without chronic kidney disease in the United States (PLUTUS). Am J Prev Cardiol. 2025;21:100950. https:\/\/doi.org\/10.1016\/j.ajpc.2025.100950.","journal-title":"Am J Prev Cardiol"},{"key":"467_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2024.101275","volume":"54","author":"S Nie","year":"2025","unstructured":"Nie S, Zhou S, Cabrera C, et al. Characteristics of patients with undiagnosed stage\u00a03 chronic kidney disease: results from an observational study (REVEAL-CKD) in China. Lancet Reg Health West Pac. 2025;54:101275. https:\/\/doi.org\/10.1016\/j.lanwpc.2024.101275.","journal-title":"Lancet Reg Health West Pac"},{"issue":"3","key":"467_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031128","volume":"12","author":"Y Xia","year":"2023","unstructured":"Xia Y, Xia C, Wu L, Li Z, Li H, Zhang J. Systemic immune inflammation index (SII), system inflammation response index (SIRI) and risk of all-cause mortality and cardiovascular mortality: a 20-year follow-up cohort study of 42,875 US adults. J Clin Med. 2023;12(3):1128. https:\/\/doi.org\/10.3390\/jcm12031128.","journal-title":"J Clin Med"},{"issue":"11","key":"467_CR26","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012638","volume":"8","author":"JJ Carrero","year":"2019","unstructured":"Carrero JJ, Andersson Franko M, Obergfell A, Gabrielsen A, Jernberg T. HsCRP level and the risk of death or recurrent cardiovascular events in patients with myocardial infarction: a healthcare-based study. J Am Heart Assoc. 2019;8(11):e012638. https:\/\/doi.org\/10.1161\/JAHA.119.012638.","journal-title":"J Am Heart Assoc"},{"issue":"10","key":"467_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005077","volume":"6","author":"C Held","year":"2017","unstructured":"Held C, White HD, Stewart RAH, et al. Inflammatory biomarkers interleukin-6 and C-reactive protein and outcomes in stable coronary heart disease: experiences from the STABILITY (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial. J Am Heart Assoc. 2017;6(10):e005077. https:\/\/doi.org\/10.1161\/JAHA.116.005077.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"467_CR28","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1080\/13696998.2025.2542024","volume":"28","author":"JH Rudolfsen","year":"2025","unstructured":"Rudolfsen JH, Vukmirica J, Johansen P, R\u00f8der KL, Mortensen MB. Impact of systemic inflammation on healthcare resource utilization and cost in patients with atherosclerotic cardiovascular disease and chronic kidney disease. J Med Econ. 2025;28(1):1298\u2013306. https:\/\/doi.org\/10.1080\/13696998.2025.2542024.","journal-title":"J Med Econ"},{"issue":"11","key":"467_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-020-00883-3","volume":"22","author":"ON Ajala","year":"2020","unstructured":"Ajala ON, Everett BM. Targeting inflammation to reduce residual cardiovascular risk. Curr Atheroscler Rep. 2020;22(11):66. https:\/\/doi.org\/10.1007\/s11883-020-00883-3.","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"467_CR30","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1177\/1060028020922994","volume":"54","author":"YM Roman","year":"2020","unstructured":"Roman YM, Hernandez AV, White CM. The role of suppressing inflammation in the treatment of atherosclerotic cardiovascular disease. Ann Pharmacother. 2020;54(10):1021\u20139. https:\/\/doi.org\/10.1177\/1060028020922994.","journal-title":"Ann Pharmacother"},{"issue":"12","key":"467_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/cells12121581","volume":"12","author":"SP Kadatane","year":"2023","unstructured":"Kadatane SP, Satariano M, Massey M, Mongan K, Raina R. The role of inflammation in CKD. Cells. 2023;12(12):1581. https:\/\/doi.org\/10.3390\/cells12121581.","journal-title":"Cells"},{"key":"467_CR32","doi-asserted-by":"publisher","unstructured":"Zhao Y, Wang R, Ma X, et al. Distribution of C-reactive protein and its association with cardiovascular risk factors in a population-based sample of Chinese.\u00a0Dis Markers.\u00a02010;28(6):333\u2013342. https:\/\/doi.org\/10.3233\/DMA-2010-0713.","DOI":"10.3233\/DMA-2010-0713"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-026-00467-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-026-00467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:24:21Z","timestamp":1788405861000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-026-00467-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["467"],"URL":"https:\/\/doi.org\/10.1007\/s40119-026-00467-3","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Hongye Ren, Magnus Fugger, Zewei Shen, Yawei Hao, Ying Wang, and Chengyu Liu are employees of Novo Nordisk, which funded this study and provided financial support for the research described in this manuscript. Zirui Zhou, Ruoya Chen, Mei Yang, Xin Zhou, and Hangkuan Liu declare that they have no competing interests.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and received ethical approval from the Tianjin Medical University General Hospital Ethics Committee (IRB2024-YX-464-01). Data from the Tianjin Health and Medical Data Platform (THMDP) were used with approval from the Tianjin Municipal Health Commission. Patient data were anonymized and non-identifiable throughout; informed consent was waived given the retrospective nature of the study, which involved no direct patient interaction.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}